InMed Pharmaceuticals Inc. (INM)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Eric A. Adams B.S. Chem., M.I.B. | President, CEO & Director | 367.6k | -- | 1963 |
| Ms. N. Netta Jagpal | CFO & Corporate Secretary | 261.05k | -- | 1973 |
| Mr. Michael Woudenberg P.Eng. | Chief Operating Officer | 326.4k | -- | 1969 |
| Ms. Alexandra Diane-Janet Mancini M.Sc. | Senior Vice President of Clinical & Regulatory Affairs | 297.8k | -- | 1953 |
| Dr. Eric Chih-Hsien Hsu Ph.D. | Senior Vice President of Preclinical Research & Development | 306.7k | -- | 1970 |
| Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder | 133.37k | -- | 1959 |
| Colin Clancy | Senior Director of Investor Relations | -- | -- | -- |
| Mr. Jerry P. Griffin | Vice President of Sales & Marketing | -- | -- | -- |
| Dr. Shane A. Johnson Ph.D. | Senior VP & GM of BayMedica | -- | -- | -- |
| Dr. Ado Muhammad | Senior Consultant of Medical Affairs | -- | -- | -- |
InMed Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 13
Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
InMed Pharmaceuticals Inc. Earnings Date
Recent Events
December 30, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission